POM: Prescription only medicine
This information is intended for use by health professionals
PosologyThe recommended dose of anastrozole for adults including the elderly is one 1 mg tablet once a day.
Paediatric populationAnastrozole is not recommended for use in children and adolescents due to insufficient data on safety and efficacy (see sections 4.4 and 5.1).
Renal impairmentNo dose change is recommended in patients with mild or moderate renal impairment. In patients with severe renal impairment, administration of anastrozole should be performed with caution (see sections 4.4 and 5.2).
Hepatic impairmentNo dose change is recommended in patients with mild hepatic disease. Caution is advised in patients with moderate to severe hepatic impairment (see section 4.4).
Method of administrationAnastrozole should be taken orally.
GeneralAnastrozole should not be used in premenopausal women. The menopause should be defined biochemically (luteinising-hormone [LH], follicle stimulating hormone [FSH], and/or estradiol levels) in any patient where there is doubt about menopausal status. There are no data to support the use of anastrozole with LHRH analogues.Co-administration of tamoxifen or oestrogen-containing therapies with anastrozole should be avoided as this may diminish its pharmacological action (see sections 4.5 and 5.1).
Effect on bone mineral densityAs anastrozole lowers circulating oestrogen levels it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture (see section 4.8).Women with osteoporosis or at risk of osteoporosis, should have their bone mineral density formally assessed at the commencement of treatment and at regular intervals thereafter. Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored. The use of specific treatments, e.g., bisphosphonates, may stop further bone mineral loss caused by anastrozole in postmenopausal women and could be considered (see section 4.8).
Hepatic impairmentAnastrozole has not been investigated in breast cancer patients with moderate or severe hepatic impairment. Exposure to anastrozole can be increased in subjects with hepatic impairment (see section 5.2); administration of anastrozole in patients with moderate and severe hepatic impairment should be performed with caution (see section 4.2). Treatment should be based on a benefit-risk evaluation for the individual patient.
Renal impairmentAnastrozole has not been investigated in breast cancer patients with severe renal impairment. Exposure to anastrozole is not increased in subjects with severe renal impairment (GRF < 30 ml/min, see section 5.2); in patients with severe renal impairment, administration of anastrozole should be performed with caution (see section 4.2).
Paediatric populationAnastrozole is not recommended for use in children and adolescents as safety and efficacy have not been established in this group of patients (see section 5.1).Anastrozole should not be used in boys with growth hormone deficiency in addition to growth hormone treatment. In the pivotal clinical trial, efficacy was not demonstrated and safety was not established (see section 5.1). Since anastrozole reduces estradiol levels, anastrozole must not be used in girls with growth hormone deficiency in addition to growth hormone treatment. Long-term safety data in children and adolescents are not available.
Hypersensitivity to lactoseThis product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
PregnancyThere are no data from the use of anastrozole in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Anastrozole is contraindicated during pregnancy (see section 4.3).
Breast-feedingThere are no data on the use of anastrozole during lactation. Anastrozole is contraindicated during breast-feeding (see section 4.3).
FertilityThe effects of anastrozole on fertility in humans have not been studied. Studies in animals have shown reproductive toxicity (see section 5.3).
|Adverse reactions by SOC and frequency|
|Metabolism and nutrition disorders||Common||Anorexia, Hypercholesterolaemia|
|Uncommon||Hypercalcaemia (with or without an increase in parathyroid hormone)|
|Nervous system disorders||Very common||Headache|
|Common||Somnolence Carpal Tunnel Syndrome * Sensory disturbances (including paraesthesia, taste loss and taste perversion)|
|Vascular disorders||Very common||Hot flushes|
|Gastrointestinal disorders||Very common||Nausea|
|Hepatobiliary disorders||Common||Increases in alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase|
|Uncommon||Increases in gamma-GT and bilirubin Hepatitis|
|Skin and subcutaneous disorders||Very common||Rash|
|Common||Hair thinning (Alopecia) Allergic reactions|
|Rare||Erythema multiforme Anaphylactoid reaction Cutaneous vasculitis (including some reports of Henoch-Schönlein purpura) **|
|Very rare||Stevens-Johnson syndrome Angioedema|
|Musculoskeletal and connective tissue disorders||Very common||Arthralgia/joint stiffness Arthritis Osteoporosis|
|Common||Bone pain Myalgia|
|Reproductive system and breast disorders||Common||Vaginal dryness Vaginal bleeding ***|
|General disorders and administration site conditions||Very common||Asthenia|
|Undesirable effect||Anastrozole (n = 3092)||Tamoxifen (n = 3094)|
|Hot flushes||11,104 (35.7%)||1,264 (40.9%)|
|Joint pain/stiffness||1,100 (35.6%)||911 (29.4%)|
|Mood disturbances||597 (19.3%)||554 (17.9%)|
|Fatigue/asthenia||575 (18.6%)||544 (17.6%)|
|Nausea and vomiting||393 (12.7%)||384 (12.4%)|
|Fractures||315 (10.2%)||209 (6.8%)|
|Fractures of the spine, hip or wrist/Colles||133 (4.3%)||91 (2.9%)|
|Wrist/Colles fractures||67 (2.2%)||50 (1.6%)|
|Spine fractures||43 (1.4%)||22 (0.7%)|
|Hip fractures||28 (0.9%)||26 (0.8%)|
|Cataracts||182 (5.9%)||213 (6.9%)|
|Vaginal bleeding||167 (5.4%)||317 (10.2%)|
|Ischaemic cardiovascular disease||127 (4.1%)||104 (3.4%)|
|Angina pectoris||71 (2.3%)||51 (1.6%)|
|Myocardial infarct||37 (1.2%)||34 (1.1%)|
|Coronary artery disorder||25 (0.8%)||23 (0.7%)|
|Myocardial ischaemia||22 (0.7%)||14 (0.5%)|
|Vaginal discharge||109 (3.5%)||408 (13.2%)|
|Any venous thromboembolic event||87 (2.8%)||140 (4.5%)|
|Deep venous thromboembolic events including PE||48 (1.6%)||74 (2.4%)|
|Ischaemic cerebrovascular events||62 (2.0%)||88 (2.8%)|
|Endometrial cancer||4 (0.2%)||13 (0.6%)|
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
Mechanism of action and pharmacodynamic effects:Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, oestradiol is produced primarily from the conversion of androstenedione to oestrone through the aromatase enzyme complex in peripheral tissues. Oestrone is subsequently converted to estradiol. Reducing circulating oestradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, a daily dose of 1 mg of anastrozole produced oestradiol suppression of greater than 80% using a highly sensitive assay. Anastrozole does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of anastrozole up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard adrenocorticotrophic hormone ACTH challenge testing. Corticoid supplements are therefore not needed.
Clinical efficacy and safety
Advanced breast cancer
First-line therapy in postmenopausal women with advanced breast cancerTwo double-blind, controlled clinical studies of similar design (Study 1033IL/0030 and Study 1033IL/0027) were conducted to assess the efficacy of anastrozole compared with tamoxifen as first-line therapy for hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer in postmenopausal women. A total of 1,021 patients were randomised to receive 1 mg of anastrozole once daily or 20 mg of tamoxifen once daily. The primary endpoints for both trials were time to tumour progression, objective tumour response rate, and safety.For the primary endpoints, Study 1033IL/0030 showed that anastrozole had a statistically significant advantage over tamoxifen for time to tumour progression (Hazard ratio (HR) 1.42, 95% Confidence Interval (CI) [1.11, 1.82], Median time to progression 11.1 and 5.6 months for anastrozole and tamoxifen respectively, p = 0.006); objective tumour response rates were similar for anastrozole and tamoxifen. Study 1033IL/0027 showed that anastrozole and tamoxifen had similar objective tumour response rates and time to tumour progression. Results from the secondary endpoints were supportive of the results of the primary efficacy endpoints. There were too few deaths occurring across treatment groups of both trials to draw conclusions on overall survival differences.
Second-line therapy in postmenopausal women with advanced breast cancerAnastrozole was studied in two controlled clinical trials (Study 0004 and Study 0005) in postmenopausal women with advanced breast cancer who had disease progression following tamoxifen therapy for either advanced or early breast cancer. A total of 764 patients were randomised to receive either a single daily dose of 1 mg or 10 mg of anastrozole or megestrol acetate 40 mg four times a day. Time to progression and objective response rates were the primary efficacy variables. The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated. In both studies there were no significant differences between treatment arms with respect to any of the efficacy parameters.
Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patientsIn a large phase III study conducted in 9366 postmenopausal women with operable breast cancer treated for 5 years, anastrozole was shown to be statistically superior to tamoxifen in disease-free survival. A greater magnitude of benefit was observed for disease-free survival in favour of anastrozole versus tamoxifen for the prospectively defined hormone receptor positive population.Table 3
|ATAC endpoint summary: 5-year treatment completion analysis|
|Efficacy endpoints||Number of events (frequency)|
|Intention to treat population||Hormone receptor positive tumour status|
|Anastrozole (n = 3125)||Tamoxifen (n = 3116)||Anastrozole (n = 2618)||Tamoxifen (n = 2598)|
|Disease-free survivala||575 (18.4)||651 (20.9)||424 (16.2)||497 (19.1)|
|2-sided 95% CI||0.78 to 0.97||0.73 to 0.94|
|Distant disease-free survivalb||500 (16.0)||530 (17.0)||370 (14.1)||394 (15.2)|
|2-sided 95% CI||0.83 to 1.06||0.80 to 1.07|
|Time to recurrencec||402 (12.9)||498 (16.0)||282 (10.8)||370 (14.2)|
|2-sided 95% CI||0.70 to 0.90||0.64 to 0.87|
|Time to distant recurrenced||324 (10.4)||375 (12.0)||226 (8.6)||265 (10.2)|
|2-sided 95% CI||0.74 to 0.99||0.70 to 1.00|
|Contralateral breast primary||35 (1.1)||59 (1.9)||26 (1.0)||54 (2.1)|
|2-sided 95% CI||0.39 to 0.89||0.30 to 0.76|
|Overall survivale||411 (13.2)||420 (13.5)||296 (11.3)||301 (11.6)|
|2-sided 95% CI||0.85 to 1.12||0.83 to 1.14|
Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patients being treated with adjuvant tamoxifenIn a phase III trial (Austrian Breast and Colorectal Cancer Study Group [ABCSG] 8) conducted in 2579 postmenopausal women with hormone receptor positive early breast cancer who had received surgery with or without radiotherapy and no chemotherapy, switching to anastrozole after 2 years adjuvant treatment with tamoxifen was statistically superior in disease-free survival when compared to remaining on tamoxifen, after a median follow-up of 24 months. Table 4
|ABCSG 8 trial endpoint and results summary|
|Efficacy endpoints||Number of events (frequency)|
|anastrozole (n = 1297)||tamoxifen (n = 1282)|
|Disease-free survival||65 (5.0)||93 (7.3)|
|2-sided 95% CI||0.49 to 0.92|
|Time to any recurrence||36 (2.8)||66 (5.1)|
|2-sided 95% CI||0.35 to 0.79|
|Time to distant recurrence||22 (1.7)||41 (3.2)|
|2-sided 95% CI||0.31 to 0.88|
|New contralateral breast cancer||7 (0.5)||15 (1.2)|
|2-sided 95% CI||0.19 to 1.13|
|Overall survival||43(3.3)||45 (3.5)|
|2-sided 95% CI||0.63 to 1.46|
Bone Mineral Density (BMD)In the phase III/IV study (Study of anastrozole with the Bisphosphonate Risedronate [SABRE]), , 234 postmenopausal women with hormone receptor positive early breast cancer scheduled for treatment with anastrozole 1 mg/day were stratified to low, moderate and high risk groups according to their existing risk of fragility fracture. The primary efficacy parameter was the analysis of lumbar spine bone mass density using DEXA scanning. All patients received treatment with vitamin D and calcium. Patients in the low risk group received anastrozole alone (N = 42), those in the moderate group were randomised to anastrozole plus risedronate 35 mg once a week (N = 77) or anastrozole plus placebo (N = 77) and those in the high risk group received anastrozole plus risedronate 35mg once a week (N = 38). The primary endpoint was change from baseline in lumbar spine bone mass density at 12 months.The 12-month main analysis has shown that patients already at moderate to high risk of fragility fracture showed no decrease in their bone mass density (assessed by lumbar spine bone mineral density using DEXA scanning) when managed by using anastrozole 1 mg/day in combination with risedronate 35 mg once a week. In addition, a decrease in BMD which was not statistically significant was seen in the low risk group treated with anastrozole 1 mg/day alone. These findings were mirrored in the secondary efficacy variable of change from baseline in total hip BMD at 12 months.This study provides evidence that the use of bisphosphonates should be considered in the management of possible bone mineral loss in postmenopausal women with early breast cancer scheduled to be treated with anastrozole.
Paediatric populationAnastrozole is not indicated for use in children and adolescents. Efficacy has not been established in the paediatric populations studied (see below). The number of children treated was too limited to draw any reliable conclusions on safety. No data on the potential long-term effects of anastrozole treatment in children and adolescents are available (see also section 5.3)The European Medicines Agency has waived the obligation to submit the results of studies with anastrozole in one or several subsets of the paediatric population in short stature due to growth hormone deficiency (GHD), testotoxicosis, gynaecomastia, and McCune-Albright syndrome (see section 4.2).
Short stature due to Growth Hormone DeficiencyA randomised, double-blind, multi-centre study evaluated 52 pubertal boys (aged 11 - 16 years inclusive) with GHD treated for 12 to 36 months with anastrozole 1 mg/day or placebo in combination with growth hormone. Only 14 subjects on anastrozole completed 36 months. No statistically significant difference with placebo was observed for the growth related parameters of predicted adult height, height, height SDS (standard deviation score), and height velocity. Final height data were not available. While the number of children treated was too limited to draw any reliable conclusions on safety, there was an increased fracture rate and a trend towards reduced bone mineral density in the anastrozole arm compared to placebo.
TestotoxicosisAn open-label, non-comparative, multi-centre study evaluated 14 male patients (aged 2 - 9 years) with familial male-limited precocious puberty, also known as testotoxicosis, treated with combination of anastrozole and bicalutamide. The primary objective was to assess the efficacy and safety of this combination regimen over 12 months. Thirteen out of the 14 patients enrolled completed 12 months of combination treatment (one patient was lost to follow-up). There was no significant difference in growth rate after 12 months of treatment, relative to the growth rate during the 6 months prior to entering the study.Gynaecomastia studiesTrial 0006 was a randomised, double-blind, multi-centre study of 82 pubertal boys (aged 11 - 18 years inclusive) with gynaecomastia of greater than 12 months duration treated with anastrozole 1 mg/day or placebo daily for up to 6 months. No significant difference in the number of patients who had a 50% or greater reduction in total breast volume after 6 months of treatment was observed between the anastrozole 1 mg treated group and the placebo group. Trial 0001 was an open-label, multiple-dose pharmacokinetic study of anastrozole 1 mg/day in 36 pubertal boys with gynaecomastia of less than 12 months duration. The secondary objectives were to evaluate the proportion of patients with reductions from baseline in the calculated volume of gynaecomastia of both breasts combined of at least 50% between day 1 and after 6 months of study treatment, and patient tolerability and safety. A decrease in 50% or more of total breast volume was seen in 56% (20/36) of the boys after 6 months.
McCune-Albright Syndrome studyTrial 0046 was an international, multi-centre, open-label exploratory trial of anastrozole in 28 girls (aged 2 to ≤ 10 years) with McCune-Albright Syndrome (MAS). The primary objective was to evaluate the safety and efficacy of anastrozole 1 mg/day in patients with MAS. The efficacy of study treatment was based on the proportion of patients fulfilling defined criteria relating to vaginal bleeding, bone age, and growth velocity.No statistically significant change in the frequency of vaginal bleeding days on treatment was observed. There were no clinically significant changes in Tanner staging, mean ovarian volume or mean uterine volume. No statistically significant change in the rate of increase in bone age on treatment compared to the rate during baseline was observed. Growth rate (in cm/year) was significantly reduced (p < 0.05) from pre-treatment through month 0 to month 12, and from pre-treatment to the second 6 months (month 7 to month 12).
AbsorptionAbsorption of anastrozole is rapid and maximum plasma concentrations typically occur within two hours of dosing (under fasted conditions). Food slightly decreases the rate but not the extent of absorption. The small change in the rate of absorption is not expected to result in a clinically significant effect on steady-state plasma concentrations during once daily dosing of Anastrozole 1 mg tablets. Approximately 90% to 95% of plasma anastrozole steady-state concentrations are attained after 7 daily doses, and accumulation is 3- to 4-fold.There is no evidence of time or dose-dependency of anastrozole pharmacokinetic parameters.Anastrozole pharmacokinetics are independent of age in postmenopausal women.
DistributionAnastrozole is only 40% bound to plasma proteins.
EliminationAnastrozole is eliminated slowly with a plasma elimination half-life of 40 to 50 hours. Anastrozole is extensively metabolised by postmenopausal women with less than 10% of the dose excreted in the urine unchanged within 72 hours of dosing. Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. The metabolites are excreted primarily via the urine. Triazole, the major metabolite in plasma, does not inhibit aromatase.
Renal or hepatic impairmentThe apparent clearance (CL/F) of anastrozole following oral administration, was approximately 30% lower in volunteers with stable hepatic cirrhosis than in matched controls (Study 1033IL/0014). However, plasma anastrozole concentrations in the volunteers with hepatic cirrhosis were within the range of concentrations seen in normal subjects in other trials. Plasma anastrozole concentrations observed during long-term efficacy trials in patients with hepatic impairment were within the range of plasma anastrozole concentrations seen in patients without hepatic impairment. The apparent clearance (CL/F) of anastrozole, following oral administration, was not altered in volunteers with severe renal impairment (GFR <30ml/min) in Study 1033IL/0018, consistent with the fact that anastrozole is eliminated primarily by metabolism. Plasma anastrozole concentrations observed during long-term efficacy trials in patients with renal impairment were within the range of plasma anastrozole concentrations seen in patients without renal impairment. In patients with severe renal impairment, administration of anastrozole should be performed with caution (see sections 4.2 and 4.4).
Paediatric populationIn boys with pubertal gynaecomastia (10-17 years), anastrozole was rapidly absorbed, was widely distributed, and was eliminated slowly with a half-life of approximately 2 days. Clearance of anastrozole was lower in girls (3-10 years) than in the older boys and exposure higher. Anastrozole in girls was widely distributed and slowly eliminated.
Acute toxicityIn animal studies toxicity was only seen at high doses. In acute toxicity studies in rodents, the median lethal dose of anastrozole was greater than 100 mg/kg/day by the oral route and greater than 50 mg/kg/day by the intraperitoneal route. In an oral acute toxicity study in the dog, the median lethal dose was greater than 45 mg/kg/day.
Chronic toxicityIn animal studies adverse effects were only seen at high doses. Multiple dose toxicity studies utilised rats and dogs. No no-effect levels were established for anastrozole in the toxicity studies, but those effects that were observed at the low doses (1 mg/kg/day) and mid doses (dog 3 mg/kg/day; rat 5 mg/kg/day) were related to either the pharmacological or enzyme-inducing properties of anastrozole and were unaccompanied by significant toxic or degenerative changes.
MutagenicityGenetic toxicology studies with anastrozole show that it is not a mutagen or a clastogen.
Reproductive toxicologyIn a fertility study weanling male rats were dosed orally with 50 or 400 mg/1 anastrozole via their drinking water for 10 weeks. Measured mean plasma concentrations were 44.4 (± 14.7) ng/ml and 165 (± 90) ng/ml respectively. Mating indices were adversely affected in both dose groups, whilst a reduction in fertility was evident only at the 400 mg/1 dose level. The reduction was transient as all mating and fertility parameters were similar to control group values following a 9-week treatment-free recovery period.Oral administration of anastrozole to female rats produced a high incidence of infertility at 1 mg/kg/day and increased pre-implantation loss at 0.02 mg/kg/day. These effects occurred at clinically relevant doses. An effect in man cannot be excluded. These effects were related to the pharmacology of the compound and were completely reversed after a 5-week compound withdrawal period.Oral administration of anastrozole to pregnant rats and rabbits caused no teratogenic effects at doses up to 1.0 and 0.2 mg/kg/day respectively. Those effects that were seen (placental enlargement in rats and pregnancy failure in rabbits) were related to the pharmacology of the compound.The survival of litters born to rats given anastrozole at 0.02mg/kg/day and above (from day 17 of pregnancy to day 22 post-partum) was compromised. These effects were related to the pharmacological effects of the compound on parturition. There were no adverse effects on behaviour or reproductive performance of the first generation offspring attributable to maternal treatment with anastrozole.
CarcinogenicityA two-year rat oncogenicity study resulted in an increase in incidence of hepatic neoplasms and uterine stromal polyps in females and thyroid adenomas in males at the high dose (25 mg/kg/day) only. These changes occurred at a dose which represents 100-fold greater exposure than occurs at human therapeutic doses, and are considered not to be clinically relevant to the treatment of patients with anastrozole. A two-year mouse oncogenicity study resulted in the induction of benign ovarian tumours and a disturbance in the incidence of lymphoreticular neoplasms (fewer histiocytic sarcomas in females and more deaths as a result of lymphomas). These changes are considered to be mouse-specific effects of aromatase inhibition and not clinically relevant to the treatment of patients with anastrozole.
Tablet coreLactose monohydrateSodium starch glycolate (type A)Povidone (K31) (E1201)Magnesium stearate (E572)
Film-coatingMacrogol 400Hypromellose (E464)Titanium dioxide (E171)